Intravitreal ranibizumab for neovascular glaucoma: an interventional case series
Objective: To evaluate the efficacy of ranibizumab in treating neovascular glaucoma.
Design: Prospective interventional case series.
Participants: Six eyes of 6 patients.
Method: Six eyes with refractory neovascular glaucoma were treated with one dose of 0.5 mg intravitreal ranibizumab followed by laser panretinal photocoagulation. Patients were divided into 2 groups based on angle status for comparison. Recurrence was defined as re-emergence of iris neovascularization, and an intraocular pressure of more than 21 mm Hg after stabilization.
Results: The patients’ mean age was 59 years and the mean follow-up 23 weeks. Three eyes had open-angle glaucoma, and three had a closed-angle configuration glaucoma. In 5 (83%) of the eyes, neovascularization completely regressed within the first 48 hours of intravitreal ranibizumab injection. Overall mean intraocular pressure dropped from 27.0 mm Hg pre- treatment to 18.3 mm Hg 1 week post–intravitreal ranibizumab. The mean anti-glaucoma drop usage decreased from 4.2 pre-treatment to 2.2 one month later. There was no recurrence throughout the initial 3 months, but 2 eyes with closed-angle configuration glaucoma recurred, with a mean time to recurrence of 14 weeks.
Conclusions: These results suggested that intravitreal ranibizumab is a useful and safe adjunct in the management of neovascular glaucoma.
How to Cite
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.